在患有微观多炎的患者和患有多炎的颗粒瘤症患者的血清中表达化学基因
Ji Eun Lee1, Taejun Yoon2, Sang-Won Lee3,4
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Scientific reports
|April 15, 2024
概括
这项研究发现,血清中化学因子CCL4,CXCL1和CX3CL1的水平与微观多炎 (MPA) 和多炎 (GPA) 颗粒瘤的疾病活性相关. 一个CX3CL1水平高于2408.92 pg/mL有效地预测了活跃的MPA/GPA.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 生物化学 生物化学
背景情况:
- 微观多炎 (MPA) 和具有多炎的颗粒炎 (GPA) 是系统性血管性炎症,其特征是小血管的炎症.
- 化基因是炎症和免疫细胞贩运的关键媒介,可能在MPA/GPA的病原发生中发挥作用.
- 了解化学激素表达和疾病活动之间的关系对于开发向疗法和改善患者治疗结果至关重要.
研究的目的:
- 在患有MPA/GPA的患者中研究特定化学因子 (CCL2,CCL4,CCL19,CXCL1,CXCL2,CX3CL1) 的表达.
- 为了确定血清化学基因水平与疾病活动的客观指标之间的相关性,例如伯明翰血管炎活动评分 (BVAS) 和五因素评分 (FFS).
- 为了确定潜在的化基因生物标志物来预测MPA/GPA中的活性疾病.
主要方法:
- 来自80名被诊断为MPA/GPA的患者的血清样本使用多种酶相关免疫吸收试验 (ELISA) 进行了分析,以量化化基因水平.
- 皮尔森的相关性分析被用来评估化学激素度和疾病活性得分之间的关系.
- 使用接收器操作员特征 (ROC) 曲线分析和多变量逻辑回归来确定最佳的CX3CL1值来预测活跃疾病,并评估疾病活动的预测因素.
主要成果:
- 血清中CCL4,CXCL1和CX3CL1的水平与BVAS有显著的正相关性.
- 此外,CX3CL1水平与FFS也有显著的负相关性.
- 多变量分析发现血清CX3CL1水平大于2408.92 pg/mL作为活性MPA/GPA的显著预测因子,赔率比为27.401 (p < 0.001).
- 还观察到各种化学激素对之间存在显著的相关性,包括CCL2/CCL4,CCL4/CXCL1,CCL4/CXCL2和CXCL1/CXCL2.
结论:
- 血清化学基因水平,特别是CCL4,CXCL1和CX3CL1,与MPA/GPA患者的疾病活性有关.
- CX3CL1成为一个有前途的生物标志物,高水平 (>2408.92 pg/mL) 强烈预测MPA/GPA中的活跃疾病.
- 这些发现突显了针对治疗干预的化学激素通路的潜力,并强调了CX3CL1作为MPA/GPA管理中的预测标记物的实用性.
更多相关视频
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
9.5K
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
424
相关概念视频
DNA Microarrays
Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
